Emilie Lardenois
Overview
Explore the profile of Emilie Lardenois including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
14
Citations
58
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Gauchotte G, Bedel C, Lardenois E, Hergalant S, Cuglietta L, Pflaum R, et al.
Cancers (Basel)
. 2023 Jan;
15(2).
PMID: 36672484
The aim of this study was to evaluate the prognostic value of MCM6, in comparison with Ki-67, in two series of grade 1 and 2 meningiomas, and to evaluate its...
2.
Gauchotte G, Bochnakian A, Campoli P, Lardenois E, Brix M, Simon E, et al.
Front Med (Lausanne)
. 2022 Jun;
9:910093.
PMID: 35665361
Background: The determination of skin wound vitality based on tissue sections is a challenge for the forensic pathologist. Histology is still the gold standard, despite its low sensitivity. Immunohistochemistry could...
3.
Ohayon M, Campoli P, Martrille L, Brix M, Kopp Q, Cohet M, et al.
Ann Pathol
. 2022 Mar;
42(6):448-457.
PMID: 35272864
Aim Of The Study: In forensic pathology, wound age evaluation allows to determine if a wound was inflicted before or after death, and to date wounds of different ages. This...
4.
Fumet J, Lardenois E, Ray-Coquard I, Harter P, Joly F, Canzler U, et al.
Cancers (Basel)
. 2022 Mar;
14(5).
PMID: 35267497
Background: Following disappointing results with PD-1/PD-L1 inhibitors in ovarian cancer, it is essential to explore other immune targets. The aim of this study is to describe the tumor immune microenvironment...
5.
Grandmougin D, Bouhlel M, Lardenois E, Donaint P, Benigni P, Sbaffi A, et al.
JACC Case Rep
. 2021 Nov;
3(15):1711-1715.
PMID: 34766024
MALT lymphoma is a non-Hodgkin lymphoma developing from B cells and is a type of marginal zone lymphoma. It can develop in any organs, but no case of primary cardiac...
6.
Fritz C, Jaeger D, Luo Y, Lardenois E, Badat B, Roquet F, et al.
Shock
. 2021 Oct;
58(2):119-127.
PMID: 34710880
Background: Optimal ventilation during cardio-pulmonary resuscitation (CPR) is still controversial. Ventilation is expected to provide sufficient arterial oxygen content and adequate carbon dioxide removal, while minimizing the risk of circulatory...
7.
Barbe J, Escobar G, Marzouki-Zerouali A, Lardenois E, Schmutz J, Bursztejn A
Int J Dermatol
. 2020 Nov;
60(4):e146-e147.
PMID: 33249555
No abstract available.
8.
Treffel M, Lardenois E, Larousserie F, Karanian M, Gomez-Brouchet A, Bouvier C, et al.
Am J Surg Pathol
. 2019 Oct;
44(1):1-10.
PMID: 31651524
Denosumab, an antibody directed against receptor activator of nuclear factor-κB ligand (RANKL), has recently been introduced in the treatment strategy of giant cell tumor of bone. In this study, we...
9.
Pouget C, Hergalant S, Lardenois E, Lacomme S, Houlgatte R, Carpentier C, et al.
Brain Pathol
. 2019 Sep;
30(3):465-478.
PMID: 31561286
Anaplastic oligodendroglioma (AO), IDH-mutant and 1p/19q codeleted (IDHmut+/1p19qcodel), is a high-grade glioma with only limited prognostic markers. The primary objective of this study was to evaluate, by immunohistochemistry, the prognostic...
10.
Fatal left coronary artery dissection due to blunt chest trauma: A case report and literature review
Violon F, Lardenois E, Grafiadis P, Martrille L, Gauchotte G
Med Sci Law
. 2019 Jun;
59(4):214-218.
PMID: 31248322
No abstract available.